Back to Sites Gaborone CRS Site Number 12701 Address Gaborone Prevention/Treatment Trials CRS Princess Marina Hospital Plot 1836, North Ring Road Gaborone, Botswana IMPAACT Members at this Site Unoda Chakalisa CRS Coordinator Tebogo Kakhu CRS Coordinator Anthony Ogwu CRS Leader Ayotunde Omoz-Oarhe CRS Leader Tendani Gaolathe CRS Staff Loeto Mazhani CRS Staff Mompati Mmalane CRS Staff Sylvester Musa-Aisien CRS Staff Gaerolwe Masheto CTU Coordinator Shahin Lockman CTU Principal Investigator Joseph Makhema CTU Principal Investigator Sue Welsch DAIDS PO Sikhulile Moyo Laboratory Director Terence Mohammed Laboratory Manager/Supervisor Lesedi Tirelo Laboratory QA/QC Coordinator Motswedi Anderson Laboratory Technician/Technologist Rufaro Mangwarara Pharmacist Yvonne Mugodi Pharmacist Tshepho Frank Pharmacy Supervisor Urunduruka Munamava QA/QC Coordinator Tumalano Sekoto Regulatory Coordinator Taolo Modise Research Nurse Mpho Raesi Research Nurse Aida Asmelash Staff Gaerolwe Masheto Staff Tebogo Mokotedi Staff Akeem Salawu Staff Dichaba Siane Staff Ponego Ponatshego Study Coordinator Mpho Raesi Study Coordinator Studies at this Site IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development